{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:16:23Z","timestamp":1792696583872,"version":"4.5.0"},"reference-count":70,"publisher":"MDPI AG","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:p>Onychomycosis is a fungal infection of the nail primarily caused by the dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes. The topical-based treatment of onychomycosis remains a challenge because of the difficulty associated with penetrating the dense, protective structure of the keratinized nail plate. Tavaborole is a novel small-molecule antifungal agent recently approved in the United States for the topical treatment of toenail onychomycosis. The low molecular weight, slight water solubility, and boron chemistry of tavaborole maximize nail penetration after topical application, allowing for effective targeting of the infection in the nail bed. The efficacy of tavaborole is associated with its novel mechanism of action, whereby it inhibits the fungal leucyl-tRNA synthetase (LeuRS) enzyme. Because LeuRS is an essential component in fungal protein synthesis, inhibition of LeuRS ultimately leads to fungal cell death. Tavaborole is the first boron-based antifungal medication approved for the treatment of mild-to-moderate onychomycosis and presents patients with a new topical option. Previously, ciclopirox and efinaconazole were the only approved topical treatments for onychomycosis. This article details the properties that are at the core of the clinical benefits associated with tavaborole.<\/jats:p>","DOI":"10.7547\/16-154","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T10:55:17Z","timestamp":1521197717000},"page":"12-19","source":"Crossref","is-referenced-by-count":25,"title":["Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis"],"prefix":"10.3390","volume":"108","author":[{"given":"Bryan","family":"Markinson","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tate","family":"Winter","sequence":"additional","affiliation":[{"name":"Sandoz, a Novartis division, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rycerz","sequence":"additional","affiliation":[{"name":"Sandoz, a Novartis division, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rock","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer, Inc, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"ref511","first-page":"13","article-title":"From the test tube to the treatment room: fundamentals of boron-containing compounds and their relevance to dermatology","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref371","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","article-title":"Recent progress on the topical therapy of onychomycosis","volume":"16","author":"Alley","year":"2007","journal-title":"Exp Opin Invest Drugs"},{"key":"ref611","first-page":"1124","article-title":"The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis","volume":"13","author":"Toledo-Bahena","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/embor.2009.2","article-title":"Not boring at all: boron is the new carbon in the quest for novel drug candidates","volume":"10","author":"Hunter","year":"2009","journal-title":"EMBO Rep"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bjid.2013.08.005","article-title":"Microsporum spp. onychomycosis: disease presentation, risk factors and treatment responses in an urban population","volume":"18","author":"Martinez","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"ref281","first-page":"10","article-title":"The role of topical antifungal therapy for onychomycosis and the emergence of newer agents","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"e1004105","DOI":"10.1371\/journal.ppat.1004105","article-title":"Fungal nail infections (onychomycosis): a never-ending story?","volume":"10","author":"Ghannoum","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2009.11.019","article-title":"Investigation of different formulations for drug delivery through the nail plate","volume":"386","author":"Vejnovic","year":"2010","journal-title":"Int J Pharm"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(96)90061-4","article-title":"Onychomycosis: a significant medical disorder","volume":"35","author":"Scher","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"ref191","first-page":"609","article-title":"In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical","volume":"14","author":"Coronado","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2494.2012.00711.x","article-title":"In vivo measurement of the surface energy of human fingernail plates","volume":"34","author":"Murdan","year":"2012","journal-title":"Int J Cosmet Sci"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2014008464","article-title":"Drug delivery to the nail: therapeutic options and challenges for onychomycosis","volume":"31","author":"Barot","year":"2014","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2494.2012.00711.x","article-title":"In vivo measurement of the surface energy of human fingernail plates","volume":"34","author":"Murdan","year":"2012","journal-title":"Int J Cosmet Sci"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.2042-7158.1997.tb06127.x","article-title":"In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy","volume":"49","author":"Mertin","year":"1997","journal-title":"J Pharm Pharmacol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2133.2003.05242.x","article-title":"Guidelines for treatment of onychomycosis","volume":"148","author":"Roberts","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref211","first-page":"675","article-title":"In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails","volume":"14","author":"Vlahovic","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2014.11.017","article-title":"Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective","volume":"199","author":"Elsayed","year":"2015","journal-title":"J Control Release"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2230.2004.01543.x","article-title":"Is slow nail growth a risk factor for onychomycosis?","volume":"29","author":"Yu","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/embor.2009.2","article-title":"Not boring at all: boron is the new carbon in the quest for novel drug candidates","volume":"10","author":"Hunter","year":"2009","journal-title":"EMBO Rep"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2014008464","article-title":"Drug delivery to the nail: therapeutic options and challenges for onychomycosis","volume":"31","author":"Barot","year":"2014","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"ref241","first-page":"1124","article-title":"The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis","volume":"13","author":"Toledo-Bahena","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"ref231","article-title":"Nail penetration and nail concentration of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis","author":"Hold","journal-title":"2006 AAPS Annual Meeting and Exposition"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0005-2795(73)90303-6","article-title":"A comparative study of the physicochemical properties of human keratinized tissues","volume":"322","author":"Baden","year":"1973","journal-title":"Biochim Biophys Acta"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","article-title":"A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns","volume":"43","author":"Ghannoum","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2230.2004.01543.x","article-title":"Is slow nail growth a risk factor for onychomycosis?","volume":"29","author":"Yu","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","article-title":"Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies","volume":"73","author":"Elewski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med Chem"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/AAC.03774-14","article-title":"Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections","volume":"59","author":"O'Dwyer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","article-title":"A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns","volume":"43","author":"Ghannoum","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2133.2003.05242.x","article-title":"Guidelines for treatment of onychomycosis","volume":"148","author":"Roberts","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1211\/0022357991772448","article-title":"Drug permeation through the three layers of the human nail plate","volume":"51","author":"Kobayashi","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"ref221","article-title":"In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis [abstract]","volume":"56:","author":"Hold","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref141","first-page":"13","article-title":"From the test tube to the treatment room: fundamentals of boron-containing compounds and their relevance to dermatology","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med Chem"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","article-title":"Recent progress on the topical therapy of onychomycosis","volume":"16","author":"Alley","year":"2007","journal-title":"Exp Opin Invest Drugs"},{"key":"ref651","first-page":"10","article-title":"The role of topical antifungal therapy for onychomycosis and the emergence of newer agents","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","article-title":"Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies","volume":"73","author":"Elewski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/jps.20901","article-title":"In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate","volume":"96","author":"Hui","year":"2007","journal-title":"J Pharm Sci"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1021\/jm0603724","article-title":"Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis","volume":"49","author":"Baker","year":"2006","journal-title":"J Med Chem"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2009.11.019","article-title":"Investigation of different formulations for drug delivery through the nail plate","volume":"386","author":"Vejnovic","year":"2010","journal-title":"Int J Pharm"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1211\/0022357991772448","article-title":"Drug permeation through the three layers of the human nail plate","volume":"51","author":"Kobayashi","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"ref491","first-page":"662","article-title":"AN-2690, a novel antifungal for the topical treatment of onychomycosis","volume":"8","author":"Barak","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-3083.2009.03426.x","article-title":"Growth rate of human fingernails and toenails in healthy American young adults","volume":"24","author":"Yaemsiri","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref591","article-title":"In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis [abstract]","volume":"56:","author":"Hold","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"e1004105","DOI":"10.1371\/journal.ppat.1004105","article-title":"Fungal nail infections (onychomycosis): a never-ending story?","volume":"10","author":"Ghannoum","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref601","article-title":"Nail penetration and nail concentration of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis","author":"Hold","journal-title":"2006 AAPS Annual Meeting and Exposition"},{"key":"ref711","first-page":"3","article-title":"\u201cModels for Skin Absorption and Skin Toxicity Testing,\u201d","author":"Schaefer","year":"2007","journal-title":"Drug Absorption Studies: In Situ, In Vitro and In Silico Models"},{"key":"ref121","first-page":"662","article-title":"AN-2690, a novel antifungal for the topical treatment of onychomycosis","volume":"8","author":"Barak","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch Dermatol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"ref581","first-page":"675","article-title":"In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails","volume":"14","author":"Vlahovic","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/jps.20901","article-title":"In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate","volume":"96","author":"Hui","year":"2007","journal-title":"J Pharm Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","article-title":"Toenail onychomycosis: an important global disease burden","volume":"35","author":"Thomas","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1021\/jm0603724","article-title":"Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis","volume":"49","author":"Baker","year":"2006","journal-title":"J Med Chem"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-3083.2009.03426.x","article-title":"Growth rate of human fingernails and toenails in healthy American young adults","volume":"24","author":"Yaemsiri","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref561","first-page":"609","article-title":"In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical","volume":"14","author":"Coronado","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bjid.2013.08.005","article-title":"Microsporum spp. onychomycosis: disease presentation, risk factors and treatment responses in an urban population","volume":"18","author":"Martinez","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0005-2795(73)90303-6","article-title":"A comparative study of the physicochemical properties of human keratinized tissues","volume":"322","author":"Baden","year":"1973","journal-title":"Biochim Biophys Acta"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.2042-7158.1997.tb06127.x","article-title":"In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy","volume":"49","author":"Mertin","year":"1997","journal-title":"J Pharm Pharmacol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2014.11.017","article-title":"Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective","volume":"199","author":"Elsayed","year":"2015","journal-title":"J Control Release"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/AAC.03774-14","article-title":"Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections","volume":"59","author":"O'Dwyer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch Dermatol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","article-title":"Toenail onychomycosis: an important global disease burden","volume":"35","author":"Thomas","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"ref01","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref341","first-page":"3","article-title":"\u201cModels for Skin Absorption and Skin Toxicity Testing,\u201d","author":"Schaefer","year":"2007","journal-title":"Drug Absorption Studies: In Situ, In Vitro and In Silico Models"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(96)90061-4","article-title":"Onychomycosis: a significant medical disorder","volume":"35","author":"Scher","year":"1996","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/108\/1\/12\/1404813\/16-154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/108\/1\/12\/1404813\/16-154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:17:22Z","timestamp":1783505842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/108\/1\/12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.7547\/16-154","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]}}}